Fig. 3.

All-cause and cHL-related outpatient visits in the weighted¹ pembrolizumab and nivolumab cohort. CCI Charlson Comorbidity Index, cHL classical Hodgkin lymphoma, CI confidence interval, DSM-V Diagnostic and Statistical Manual of Mental Disorders, 5th edition, IPTW inverse probability of treatment weighting, PPY per person-year, RR rate ratio. 1 IPTW weights based on the propensity score were derived from a multivariable logistic model conditional on baseline covariates including age, sex, region, type of insurance coverage, year of index date, Quan-CCI, number of hospitalizations, number of outpatient visits, any anti-cancer therapy use, and all Elixhauser and DSM-V comorbidities ≥ 10% prevalence in either cohort. 2 Rate ratios were obtained from Poisson regression models with log-link; confidence intervals and p-values were calculated using non-parametric bootstrap procedure methods with 999 replications